Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Melissa Rainey

Nurse Practitioner, Family Charleston, WV Nurse Practitioner

NPI 1689235798 CMS profile 10645579

3701 MacCorkle Ave Se, Charleston, WV 25304

Open in the dashboard

General payments

$6,694

425 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melissa Rainey of Charleston, WV is reported in the CMS Open Payments database as having received $6,694 across 425 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,235 76
2024 General $1,177 66
2023 General $1,479 98
2022 General $1,508 96
2021 General $1,296 89

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melissa Rainey
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Melissa Rainey were reported at $1,235. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Melissa Rainey Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,296 $124 $35–$379 $132
2022 $1,508 $141 $44–$430 $149
2023 $1,479 $154 $49–$476 $160
2024 $1,177 $165 $51–$504 $164
2025 $1,235 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,725 141 payments
  2. AbbVie, Inc. $1,351 70 payments
  3. Novartis Pharmaceuticals Corporation $544 31 payments
  4. Lilly USA, LLC $391 24 payments
  5. Amgen Inc. $376 27 payments
  6. AstraZeneca Pharmaceuticals LP $330 21 payments
  7. Astellas Pharma US Inc $181 8 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $170 10 payments
  9. Merck Sharp & Dohme Corporation $156 8 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $140 9 payments
  11. Other $1,330 76 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,694 425 payments
Products named General payments · program years 2021–2025
  1. RYBELSUS $1,464 124 payments
  2. Ozempic $1,427 127 payments
  3. UBRELVY $776 37 payments
  4. QULIPTA $716 38 payments
  5. LEQVIO $365 20 payments
  6. VRAYLAR $238 15 payments
  7. NURTEC ODT $203 11 payments
  8. JARDIANCE $199 10 payments
  9. FARXIGA $171 10 payments
  10. Kerendia $170 10 payments
  11. Other $3,571 217 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 77 drugs

Part D claims

2,682

Median for Nurse Practitioner: 389

Drug cost

$259,656

Median for Nurse Practitioner: $21,885

Branded share of claims

17.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 46 $85,294
Rexulti Brexpiprazole Brand 15 $38,934
Eliquis Apixaban Brand 36 $38,466
Jardiance Empagliflozin Brand 26 $33,058
Mounjaro Tirzepatide Brand 11 $13,434
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 12 $11,371
Tresiba Flextouch U-100 Insulin Degludec Brand 15 $5,428
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 12 $3,765
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 23 $3,756
Metoprolol Succinate Generic 94 $1,801

The 10 drugs with the highest cost, of 77 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$20,229

Of which drugs: $85

Medicare patients

74

Average age 72

Services billed

562

53 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Depression 47%
Chronic kidney disease 45%
Ischemic heart disease 39%
Diabetes 38%
Atrial fibrillation 27%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBELSUS
  • Novo Nordisk Inc $153
$153 — —
Ozempic
  • Novo Nordisk Inc $153
$153 46 —
UBRELVY
  • AbbVie, Inc. $90
$90 — —
QULIPTA
  • AbbVie, Inc. $90
$90 — —
VRAYLAR
  • AbbVie, Inc. $70
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

425 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record